Journal: International immunology

Article Title: Effects of BCL-2 over-expression on B cells in transgenic rats and rat hybridomas.

doi: 10.1093/intimm/dxr071

Figure Lengend Snippet: Fig. 6. Hybridoma characterization. (A) Binding constants (nanomolar) of mAbs generated with splenocytes from non-transgenic littermates (LM) and transgenic line 70818 animals (Bcl2) as determined by Biacore analysis (log scale nanomolar). (B) Western blot analysis of Bcl-2 expression in hybridomas from bcl-2 transgenic animals (each line represents one hybridoma). The positive control corresponds to a lysate from human Jurkat cells. The ratio of Bcl-2/GAPDH for each hybridoma is depicted under the respective lines. (C) Concentration of rat IgG in tissue culture supernatants at day 3 of culture (cells between 3.1 and 6 3 105 ml–1) measured by ELISA. Each point represents the values of one hybridoma supernatant and the horizontal bar the mean of each group of values *P < 0.05 hybridoma Bcl-2- (n = 4) versus hybridoma Bcl-2+

Article Snippet: Western blots were performed as previously described (26) using a mouse anti-human Bcl2 mAb (Abd Serotec) followed by incubation with HRP-conjugated goat anti-mouse IgG + IgM (H + L) antibodies (Jackson ImmunoResearch).

Techniques: Binding Assay, Generated, Transgenic Assay, Western Blot, Expressing, Positive Control, Concentration Assay, Enzyme-linked Immunosorbent Assay

Journal: Oncology letters

Article Title: Tanshinone IIA potentiates the efficacy of imatinib by regulating the AKT-MDM2-P53 signaling pathway in Philadelphia chromosome-positive acute lymphoblastic leukemia.

doi: 10.3892/ol.2021.13125

Figure Lengend Snippet: Figure 5. Effects of Tan and Im on BCR/ABL signaling and apoptosis‑regulatory proteins in Philadelphia chromosome‑positive acute lymphoblastic leukemia. SUP‑B15 cells were treated with 0.1% DMSO (control), 2 µM Im, 4 µM Tan or the combination of 2 µM Im and 4 µM Tan for 24 and 48 h. SUP‑B15/RI cells were treated with 0.1% DMSO (control), 10 µM Im, 8 µM Tan or the combination of 10 µM Im and 8 µM Tan for 24 h and 48 h. At the end of the treatments, the cells were collected, and the total proteins were extracted for western blot analysis using the corresponding antibodies. One representative western blot is presented. GAPDH was used as the loading control. (A) Effects of Tan and Im on the activation of BCR/ABL, STAT5 and MEK in SUP‑B15 cells. (B) Effects of Tan and Im on the activation of BCR/ABL, STAT5 and MEK in SUP‑B15/RI cells. (C) Effects of Tan and Im on the anti‑apoptotic proteins BCL2 and MCL1 in SUP‑B15. (D) Effects of Tan and Im on the anti‑apoptotic proteins BCL2 and MCL1 in SUP‑B15/RI. Im, imatinib; MCL1, MCL1 apoptosis regulator, BCL2 family member; p‑, phosphorylated; Tan, tanshinone IIA.

Article Snippet: The antibody against MCL1 apoptosis regulator, BCL2 family member (MCL1) was purchased from OriGene Technologies, Inc.

Techniques: Control, Western Blot, Activation Assay